US2019367456A1PendingUtilityA1
Biaryl compositions and methods for modulating a kinase cascade
Est. expiryApr 13, 2027(~0.8 yrs left)· nominal 20-yr term from priority
Inventors:David G. Hangauer, Jr.
A61P 43/00A61P 37/06A61P 9/10A61P 9/00A61P 3/10A61P 35/02A61P 31/04A61P 27/02A61P 25/04A61P 33/00A61P 35/00A61P 31/10A61P 27/16A61P 31/12A61P 3/04A61P 19/10A61P 17/06C07D 213/56C07D 213/52C07D 403/12C07D 401/14C07D 213/89C07D 401/12C07D 401/04
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to compounds and methods for modulating one or more components of a kinase cascade.
Claims
exact text as granted — not AI-modified1 .- 19 . (canceled)
20 . A composition comprising tamoxifen and a compound of Formula I:
or a salt, solvate, hydrate, or prodrug thereof, wherein:
T is a bond, CR 12 R 13 , C(O), O, S, S(O), S(O) 2 , NR 14 , C(R 15 R 16 )C(R 17 R 18 ), CH 2 O, or OCH 2 ;
X y is CZ, CY, N, or N—O;
X z is CZ, CY, N, or N—O;
at least one of X y and X z is CZ;
Y is selected from hydrogen, hydroxyl, halogen, lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkoxy, O-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl-aryl, and O-benzyl;
X a is CR a or N, or N—O;
X b is CR b , N, or N—O;
X c is CR c or N, or N—O;
X d is CR d or N, or N—O;
X e is CR e , N, or N—O;
R a , R b , R c , R d , R e , R 4 , R 5 , and R 6 are, independently, hydrogen, hydroxyl, halogen, P, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkoxy, O-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl-aryl, O-benzyl, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl-OH, COOH, COO-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl, SO 2 H, SO 2 -lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl,
where W is H, or C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl-aryl;
P is SO 3 H, OSO 3 H, OPO 3 H 2 , OPO 3 H 2 , NH 2 , NHR 19 , NHR 20 R 21 ,
tetrazole, O-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl-K, O—C(O)-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl-L, NH-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl-M, or O-aryl-Q, further wherein lower alkyl is linear or branched alkyl;
K is C(O)NH 2 , COOH, SO 3 H, OSO 3 H, PO 3 H 2 , OPO 3 H 2 , NH 2 , NHR 19 , NR 19 R 20 , SO 20 R 21 , glycoside, lower C 1 , C 2 , C 3 , C 4 , C 5 , C 6 alkoxy, or
L is aryl, heteroaryl, OH, C(O)NH 2 , COOH, SO 3 H, OSO 3 H, PO 3 H 2 , OPO 3 H 2 , NH 2 , NHR 19 , NR 19 R 20 , SO 20 R 21 , glycoside, lower C 1 , C 2 , C 3 , C 4 , C 5 , C 6 alkoxy, or
M is aryl, heteroaryl, OH, C(O)NH 2 , COOH, SO 3 H, OSO 3 H, PO 3 H 2 , OPO 3 H 2 , NH 2 , NHR 19 , NR 19 R 20 , SO 20 R 21 , glycoside, lower C 1 , C 2 , C 3 , C 4 , C 5 , C 6 alkoxy, or
Q is aryl, heteroaryl, OH, C(O)NH 2 , COOH, SO 3 H, OSO 3 H, PO 3 H 2 , OPO 3 H 2 , NH 2 , NHR 19 , NR 19 R 20 , SO 20 R 21 , glycoside, lower C 1 , C 2 , C 3 , C 4 , C 5 , C 6 alkoxy, or
R 19 , R 20 and R 21 are C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl or R 19 and R 20 taken together with the attached nitrogen atom form a five membered ring;
V is a bond, —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, —O—CH 2 —, —OCH 2 CH 2 — or —OCH 2 CH 2 CH 2 —;
R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , and R 18 , are, independently, H or C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl;
Z is (CHR 1 ) n —C(O)—NR 2 (CHR 3 ) m —Ar, where Ar is a substituted or unsubstituted aryl or nitrogen-containing heteroaryl group, R 1 , R 2 , and R 3 are independently H or C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl; and
n and m are independently 0, 1, or 2.
21 . The composition of claim 20 , wherein at least one of X a , X b , X c , X d , X e , X y and X z is N.
22 . The composition of claim 20 , wherein X z is CZ and Z is
where R 7 , R 8 , R 9 , R 10 , and R 11 are selected from hydrogen, hydroxyl, halogen, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkoxy, O-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl-aryl, O-benzyl, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl-OH, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl-O—C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl,
where W is H, or C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl-aryl.
23 . The composition of claim 20 , wherein R 4 and R 6 are each H.
24 . The composition of claim 20 , wherein m and n are each 1 and R 2 and R 3 are each H.
25 . The composition of claim 20 , wherein the compound is selected from
26 . The composition of claim 20 , wherein the compound is
27 . The composition of claim 20 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
28 . The composition of claim 20 , wherein the compound is
29 . The composition of claim 20 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
30 . A method for treating or preventing breast cancer, comprising administering to a subject a composition comprising tamoxifen and a compound of Formula I:
or a salt, solvate, hydrate, or prodrug thereof, wherein:
T is a bond, CR 12 R 13 , C(O), O, S, S(O), S(O) 2 , NR 14 , C(R 15 R 16 )C(R 17 R 18 ), CH 2 O, or OCH 2 ;
X y is CZ, CY, N, or N—O;
X z is CZ, CY, N, or N—O;
at least one of X y and X z is CZ;
Y is selected from hydrogen, hydroxyl, halogen, lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkoxy, O-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl-aryl, and O-benzyl;
X a is CR a or N, or N—O;
X b is CR b , N, or N—O;
X c is CR c or N, or N—O;
X d is CR d or N, or N—O;
X e is CR e , N, or N—O;
R a , R b , R c , R d , R e , R 4 , R 5 , and R 6 are, independently, hydrogen, hydroxyl, halogen, P, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkoxy, O-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl-aryl, O-benzyl, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl-OH, COOH, COO-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl, SO 2 H, SO 2 -lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl,
where W is H, or C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl-aryl;
P is SO 3 H, OSO 3 H, OPO 3 H 2 , OPO 3 H 2 , NH 2 , NHR 19 , NHR 20 R 21 ,
tetrazole, O-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl-K, O—C(O)-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl-L, NH-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl-M, or O-aryl-Q, further wherein lower alkyl is linear or branched alkyl;
K is C(O)NH 2 , COOH, SO 3 H, OSO 3 H, PO 3 H 2 , OPO 3 H 2 , NH 2 , NHR 19 , NR 19 R 20 , SO 20 R 21 , glycoside, lower C 1 , C 2 , C 3 , C 4 , C 5 , C 6 alkoxy, or
L is aryl, heteroaryl, OH, C(O)NH 2 , COOH, SO 3 H, OSO 3 H, PO 3 H 2 , OPO 3 H 2 , NH 2 , NHR 19 , NR 19 R 20 , SO 20 R 21 , glycoside, lower C 1 , C 2 , C 3 , C 4 , C 5 , C 6 alkoxy, or
M is aryl, heteroaryl, OH, C(O)NH 2 , COOH, SO 3 H, OSO 3 H, PO 3 H 2 , OPO 3 H 2 , NH 2 , NHR 19 , NR 19 R 20 , SO 20 R 21 , glycoside, lower C 1 , C 2 , C 3 , C 4 , C 5 , C 6 alkoxy, or
Q is aryl, heteroaryl, OH, C(O)NH 2 , COOH, SO 3 H, OSO 3 H, PO 3 H 2 , OPO 3 H 2 , NH 2 , NHR 19 , NR 19 R 20 , SO 20 R 21 , glycoside, lower C 1 , C 2 , C 3 , C 4 , C 5 , C 6 alkoxy, or H
R 19 , R 20 and R 21 are C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl or R 19 and R 20 taken together with the attached nitrogen atom form a five membered ring;
V is a bond, —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, —O—CH 2 —, —OCH 2 CH 2 — or —OCH 2 CH 2 CH 2 —;
R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , and R 18 , are, independently, H or C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl;
Z is (CHR 1 ) n —C(O)—NR 2 (CHR 3 ) m —Ar, where Ar is a substituted or unsubstituted aryl or nitrogen-containing heteroaryl group, R 1 , R 2 , and R 3 are independently H or C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl; and
n and m are independently 0, 1, or 2.
31 . The method of claim 30 , wherein at least one of X a , X b , X c , X d , X e , X y and X z is N.
32 . The method of claim 29 , wherein X z is CZ and Z is
where R 7 , R 8 , R 9 , R 10 , and R 11 are selected from hydrogen, hydroxyl, halogen, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkoxy, O-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl-aryl, O-benzyl, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl-OH, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl-O—C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl,
where W is H, or C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl-aryl.
33 . The method of claim 30 , wherein R 4 and R 6 are each H.
34 . The method of claim 30 , wherein m and n are each 1 and R 2 and R 3 are each H.
35 . The method of claim 30 , wherein the compound is selected from
36 . The method of claim 30 , wherein the compound is
37 . The method of claim 30 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
38 . The method of claim 30 , wherein the compound is
39 . The composition of claim 30 , wherein the compound is
or a pharmaceutically acceptable salt thereof.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.